SCHEDULE: State Street Discloses 5.5% Stake in Recursion Pharmaceuticals

State Street Corporation has reported a beneficial ownership of 5.5% in Recursion Pharmaceuticals Inc. as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Recursion Pharmaceuticals Inc. common stock.
• As of March 31, 2026, State Street Corporation beneficially owns 28,490,638 shares, representing 5.5% of the class of securities.
• The filing specifies that State Street Corporation has shared voting power over 27,368,965 shares and shared dispositive power over 28,490,638 shares.
• The company's subsidiaries involved in this reporting include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of institutional ownership and does not provide new operational or financial insights into Recursion Pharmaceuticals itself.

Positives

• State Street Corporation's significant stake indicates confidence or investment strategy involving Recursion Pharmaceuticals.
• The filing is a standard disclosure, implying adherence to regulatory requirements.

Negatives

• The filing does not contain any negative financial or operational information about Recursion Pharmaceuticals itself, as it is a disclosure of ownership by an external entity.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not inherently detail specific risks for Recursion Pharmaceuticals. However, any significant shift in holdings by large institutional investors like State Street could be perceived as a market signal.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Recursion Pharmaceuticals.

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common and provide transparency into major shareholders. State Street Corporation, through its various asset management arms (like SSGA), is a significant global investor, and its holdings can reflect broad market trends or specific sector confidence.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, which can influence market perception.
• Management of Recursion Pharmaceuticals: A large stake by an institutional investor may imply a degree of stability or scrutiny from that investor.

Next Steps

• Continued monitoring of State Street Corporation's holdings in Recursion Pharmaceuticals for any future changes.
• Analysis of Recursion Pharmaceuticals' own financial reports and strategic updates to understand the underlying reasons for institutional investment.

Key Dates

Keywords

Recursion Pharmaceuticals, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment